Plasma levels of hepatocyte growth factor and placental growth factor predict mortality in a general population: a prospective cohort study
Standard
Plasma levels of hepatocyte growth factor and placental growth factor predict mortality in a general population: a prospective cohort study. / Santalahti, K; Havulinna, A; Maksimow, M; Zeller, T; Blankenberg, S; Vehtari, A; Joensuu, H; Jalkanen, S; Salomaa, V; Salmi, M.
in: J INTERN MED, Jahrgang 282, Nr. 4, 10.2017, S. 340-352.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Plasma levels of hepatocyte growth factor and placental growth factor predict mortality in a general population: a prospective cohort study
AU - Santalahti, K
AU - Havulinna, A
AU - Maksimow, M
AU - Zeller, T
AU - Blankenberg, S
AU - Vehtari, A
AU - Joensuu, H
AU - Jalkanen, S
AU - Salomaa, V
AU - Salmi, M
N1 - © 2017 The Association for the Publication of the Journal of Internal Medicine.
PY - 2017/10
Y1 - 2017/10
N2 - BACKGROUND: Circulating levels of growth factors involved in leucocyte production and angiogenesis could be indicative of underlying aberrations of tissue homeostasis and therefore be utilized as predictors of risk for all-cause cardiovascular disease (CVD) or cancer mortality.METHODS: Baseline plasma levels of a range of growth factors were measured in two cohorts of the population-based FINRISK study (1997 Discovery cohort, N = 8444, aged 25-74; 2002 Replication cohort, N = 2951, aged 51-74 years) using a multiplexed bead array methodology and ELISA. Participants were followed up by linking them to registry data.RESULTS: In the Discovery cohort (653 deaths; 216 CVD-related, 231 cancer-related), fully adjusted Cox proportional hazard regression models showed that increased plasma hepatocyte growth factor (HGF) and placental growth factor (PlGF) were associated with higher risk of 10-year mortality (HR, 1.29 [95% confidence interval (CI), 1.18-1.41] and HR, 1.23 [95% CI, 1.14-1.32], respectively). In the Replication cohort (259 deaths; 83 CVD-related, 90 cancer-related), baseline HGF levels also predicted all-cause mortality (HR, 1.2 [95% CI, 1.08-1.32]; PlGF data not available). By including HGF levels in a CVD mortality model, 9% of all CVD deaths were correctly reclassified in the Discovery cohort (categorical net reclassification improvement [NRI] for events, P = 4.0 × 10-4 ). Moreover, adding HGF to all-cause and CVD mortality models resulted in an overall clinical NRI of 0.10-0.18 in the Discovery cohort and meta-analyses (P < 0.05 for all tests).CONCLUSION: Blood levels of HGF and PlGF may serve as new biomarkers for predicting increased risk of death in the general population.
AB - BACKGROUND: Circulating levels of growth factors involved in leucocyte production and angiogenesis could be indicative of underlying aberrations of tissue homeostasis and therefore be utilized as predictors of risk for all-cause cardiovascular disease (CVD) or cancer mortality.METHODS: Baseline plasma levels of a range of growth factors were measured in two cohorts of the population-based FINRISK study (1997 Discovery cohort, N = 8444, aged 25-74; 2002 Replication cohort, N = 2951, aged 51-74 years) using a multiplexed bead array methodology and ELISA. Participants were followed up by linking them to registry data.RESULTS: In the Discovery cohort (653 deaths; 216 CVD-related, 231 cancer-related), fully adjusted Cox proportional hazard regression models showed that increased plasma hepatocyte growth factor (HGF) and placental growth factor (PlGF) were associated with higher risk of 10-year mortality (HR, 1.29 [95% confidence interval (CI), 1.18-1.41] and HR, 1.23 [95% CI, 1.14-1.32], respectively). In the Replication cohort (259 deaths; 83 CVD-related, 90 cancer-related), baseline HGF levels also predicted all-cause mortality (HR, 1.2 [95% CI, 1.08-1.32]; PlGF data not available). By including HGF levels in a CVD mortality model, 9% of all CVD deaths were correctly reclassified in the Discovery cohort (categorical net reclassification improvement [NRI] for events, P = 4.0 × 10-4 ). Moreover, adding HGF to all-cause and CVD mortality models resulted in an overall clinical NRI of 0.10-0.18 in the Discovery cohort and meta-analyses (P < 0.05 for all tests).CONCLUSION: Blood levels of HGF and PlGF may serve as new biomarkers for predicting increased risk of death in the general population.
KW - Adult
KW - Aged
KW - Biomarkers/blood
KW - Cardiovascular Diseases/mortality
KW - Female
KW - Hepatocyte Growth Factor/blood
KW - Humans
KW - Male
KW - Middle Aged
KW - Mortality
KW - Neoplasms/mortality
KW - Placenta Growth Factor/blood
KW - Predictive Value of Tests
KW - Proportional Hazards Models
KW - Prospective Studies
KW - Risk Factors
U2 - 10.1111/joim.12648
DO - 10.1111/joim.12648
M3 - SCORING: Journal article
C2 - 28682476
VL - 282
SP - 340
EP - 352
JO - J INTERN MED
JF - J INTERN MED
SN - 0954-6820
IS - 4
ER -